Anna Sturrock

Anna Sturrock

Auto-generated profile, based on publicly available information

Anna Sturrock

Department of Physiology and Medical Physics & RCSI Centre for Systems Medicine, RCSI University of Medicine and Health Sciences, 123 St Stephen’s Green, Dublin 2, Ireland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2019 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
AMAnna Matveeva
Anna Matveeva
MFMichael Fichtner
Michael Fichtner
KMKatherine McAllister
Katherine McAllister
CMChristopher McCann
Christopher McCann
MSMarc Sturrock
Marc Sturrock
Jochen PrehnJochen Prehn
Jochen Prehn
Ligand binding to death receptors activates apoptosis in cancer cells. Stimulation of death receptors results in the formation of intracellular multiprotein platforms that either activate the apoptotic initiator Caspase-8 to trigger cell death, or signal through kinases to initiate inflammatory and cell survival signalling. Two of these platforms, the Death-Inducing Signalling Complex (DISC) and the RIPoptosome, also initiate necroptosis by building filamentous scaffolds that lead to the activation of mixed lineage kinase domain-like pseudokinase. To explain cell decision making downstream of death receptor activation, we developed a semi-stochastic model of DISC/RIPoptosome formation. The model is a hybrid of a direct Gillespie stochastic simulation algorithm for slow assembly of the RIPoptosome and a deterministic model of downstream caspase activation. The model explains how alterations in the level of death receptor-ligand complexes, their clustering properties and intrinsic molecular fluctuations in RIPoptosome assembly drive heterogeneous dynamics of Caspase-8 activation. The model highlights how kinetic proofreading leads to heterogeneous cell responses and results in fractional cell killing at low levels of receptor stimulation. It reveals that the noise in Caspase-8 activation—exclusively caused by the stochastic molecular assembly of the DISC/RIPoptosome platform—has a key function in extrinsic apoptotic stimuli recognition. Death receptors are targets of novel cancer therapeutics. Most of them signal through flexible multiprotein platforms to either activate apoptotic or necroptotic cell death, or propagate cell survival and pro-inflammatory signals. We focused our study on the role of dynamic assembly and composition of these platforms in the initiation of cell death at the single cell level. Since the assembly is slow through the competitive nature of protein binding within the platforms core we developed a stochastic mathematical model of the death inducing signalling platform. Our model provided an explanation for delayed cell death and fractional killing upon the death receptor stimulation. Additionally, we found that the variability in the cell death response arises through the random assembly initiates a slow noise-prone ramp activation of initiator Caspase-8 spontaneously triggering the apoptotic cascade. Our computational simulations predicted high variation in the time required for cell death induction at the single cell level and highlighted a significant role of death receptor clustering in effective Caspase-8 activation. Our knowledge and data driven model captures detailed processes governing the early events of cell death initiation and can be used to guide the development of more rational combinational treatments against cancer.

4 March 2021 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
CMChristopher McCann
Christopher McCann
AMAnna Matveeva
Anna Matveeva
KMKatherine McAllister
Katherine McAllister
SSSandra Van Schaeybroeck
Sandra Van Schaeybroeck
TSTamas Sessler
Tamas Sessler
Daniel LongleyDaniel Longley
Daniel Longley
Resistance to chemotherapy‐induced cell death is a major barrier to effective treatment of solid tumours such as colorectal cancer, CRC. Herein, we present a study aimed at developing a proteomics‐based predictor of response to standard‐of‐care (SoC) chemotherapy in combination with antagonists of IAPs (inhibitors of apoptosis proteins), which have been implicated as mediators of drug resistance in CRC. We quantified the absolute expression of 19 key apoptotic proteins at baseline in a panel of 12 CRC cell lines representative of the genetic diversity seen in this disease to identify which proteins promote resistance or sensitivity to a model IAP antagonist [birinapant (Bir)] alone and in combination with SoC chemotherapy (5FU plus oxaliplatin). Quantitative western blotting demonstrated heterogeneous expression of IAP interactome proteins across the CRC cell line panel, and cell death analyses revealed a widely varied response to Bir/chemotherapy combinations. Baseline protein expression of cIAP1, caspase‐8 and RIPK1 expression robustly correlated with response to Bir/chemotherapy combinations. Classifying cell lines into ‘responsive’, ‘intermediate’ and ‘resistant’ groups and using linear discriminant analysis (LDA) enabled the identification of a 12‐protein signature that separated responders to Bir/chemotherapy combinations in the CRC cell line panel with 100% accuracy. Moreover, the LDA model was able to predict response accurately when cells were cocultured with Tumour necrosis factor‐alpha to mimic a pro‐inflammatory tumour microenvironment. Thus, our study provides the starting point for a proteomics‐based companion diagnostic that predicts response to IAP antagonist/SoC chemotherapy combinations in CRC.

6 August 2024 in BMJ Oncology
Verified
Journal Article
Open access
PDF file
SCSanghee Cho
Sanghee Cho
EMElizabeth McDonough
Elizabeth McDonough
JGJohn Graf
John Graf
JSJinru Shia
Jinru Shia
CFCanan Firat
Canan Firat
Fiona GintyFiona Ginty
Fiona Ginty
Objective: Inducing tumour cell apoptosis is a primary objective of chemotherapy but, to date, there are no validated biomarkers of apoptosis sensitivity or resistance. Our objective was to image multiple apoptosis pathway proteins at single cell level and determine multi-protein associations with recurrence risk and chemotherapy response in patients with stage II colorectal cancer (CRC). Methods and analysis: Multiplexed imaging of 16 proteins in the intrinsic and extrinsic apoptosis pathways at single cell resolution on resected tissue from 194 patients with stage II CRC who either received adjuvant chemotherapy (n=108) or were treated with surgery only (n=86). K-means clustering of >600 000 cancer cells and cell level intensities of APAF1, procaspase-9, procaspase-3, XIAP, SMAC, BAX, BAK, BCL2, BCL-XL, MCL-1, procaspase-8, BID, FADD, FLIP, RIP3 and CIAP1 identified distinct cell cluster profiles. Results: Chemotherapy-treated patients with a higher percentage of cell clusters with low procaspase-3 and high XIAP had a higher risk of recurrence. This was validated in an independent cohort of adjuvant chemotherapy-treated high-risk patients with stage II CRC. We also applied two established system models of apoptosis initiation and execution to estimate cellular apoptosis sensitivity and show that these cell clusters do not appear to have impaired mitochondrial outer membrane permeabilisation sensitivity, but downstream procaspase-3 cleavage is compromised. This represents a key characteristic of drug-tolerant ‘persister’ cells. Conclusion: This study represents the most comprehensive analysis to date of apoptosis protein distribution at single cell level in CRC tumours. Our study identifies a subgroup of patients with stage II CRC with an apoptosis-resistant ‘persister’ cell profile who do not benefit from adjuvant chemotherapy.

10 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
BKBatuhan Kisakol
Batuhan Kisakol
ASAnna Sturrock
Anna Sturrock
SCSanghee Cho
Sanghee Cho
MAMohammadreza Azimi
Mohammadreza Azimi
ALAndreas U. Lindner
Andreas U. Lindner
Jochen PrehnJochen Prehn
Jochen Prehn
Background: Identification of the consensus molecular subtypes (CMS) opened significant potential for understanding the tumor biology and intertumoral heterogeneity of colorectal cancer (CRC). However, molecular subtyping in CRC traditionally relies on bulk transcriptomics, therefore, lacks spatial and single-cell level aspect. Methods: We constructed tissue microarrays using tumor cores from 222 CRC patients. Arrays were stained and imaged using 54 cell identity and cancer hallmark markers, delivering spatially resolved protein profiles of >2 million cells. RNA sequencing data and CMS classification were also available for these patients. After segmentation of cancer, stromal and immune cells, we investigated intratumoral heterogeneity within CMS subtypes using spatially resolved single-cell protein profiling (>2 million cells). We compared cell types, their spatial organization and their expression of cancer hallmark-related proteins in CMS 1-4 subtypes. Results: We revealed tissue atlases illustrating the cell types/states, spatial heterogeneity, cellular neighborhoods, cellular network, and single-cell protein profiles of CMS tumors. CMS1 tumors had more CD3 + , CD8 + , and PD1 + immune cells that were found in the epithelial layer frequently. CMS1 was also associated with higher levels of metabolic reprogramming markers such as upregulated glycolysis. CMS2 showed immune segregation, reactive stroma patterns and higher levels of apoptotic and proliferative signaling proteins. CMS3 exhibited clustered cancer cells with high RIP3 levels, suggesting a pro-inflammatory microenvironment. CMS4 displayed stromal-centric and immune-evasive tumors characterized by decreased HLA-1 levels and regulatory T-cell exclusion from epithelium. Conclusion: We present a spatial protein atlas of CRC at single-cell resolution and demonstrate novel aspects of CMS tumour structures.

13 January 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAnna Sturrock
Anna Sturrock
SCSanghee Cho
Sanghee Cho
MSManuela Salvucci
Manuela Salvucci
MSMarc Sturrock
Marc Sturrock
JFJoanna Fay
Joanna Fay
Jochen PrehnJochen Prehn
Jochen Prehn
Background: Stage III colorectal cancer poses a significant threat of metastasis development, as tumour resection and adjuvant chemotherapy do not guarantee prolonged disease-free survival. Objective: The spatial, quantitative, and qualitative characteristics of various cell types within tumour tissues could be key to developing accurate prognostic AI models. Design: Tissue microarrays created from primary tumour tissues collected during surgical resection from a cohort of 493 stage III colorectal cancer (CRC) patients were analysed for 61 protein markers at the single-cell level using multiplexed immunofluorescence imaging via the Cell DIVE™ platform. Subsequent cell-type classification enabled quantitative cell-type analyses, co-localisation neighbourhood assessments, and cell-type-specific protein signature discoveries that distinguish between early and late/non-recurring patient samples. Results: This study identifies a stem cell protein profile that drives tumour relapse. A deep neural network (DNN) model, based on a stem cell protein signature composed of BAX, MLKL, FLIP, GLUT1, and CDX2, provided accurate prognosis for stage III CRC patients in both discovery and validation cohorts and in an independent validation cohort. Nodal count-based metric further increased prognosis accuracy. Our study also revealed distinct spatial arrangements of immune, endothelial, and stem cells that were linked to early tumour recurrence. Conclusion: Our findings propose a clinically promising prognostic tool based on a five-protein stem cell signature. These markers not only predict chemotherapy resistance in cancer stem cells but also suggest potential therapeutic strategies such as combinatorial treatments incorporating small molecule inhibitors targeting FLIP and GLUT1. Key messages: What is already known on this topic: More than 20% of stage III colorectal cancer patients will experience early tumour recurrence within the first 3 years post treatment that includes surgery and adjuvant 5-FU based chemotherapy treatment. Several studies pointed towards involvements of number of cell type specific spatial neighbourhoods in tumour progression where some immune tumour microenvironment promoting angiogenesis and intravasation events, some may provide immunosuppression. Cancer stem cells could be responsible for metastatic tumour spread, early recurrence and chemoresistance. What this study adds: Spatial single cell quantitative multiplex profiling of 45 cancer hallmark proteins and 15 cell identity markers in 493 stage III CRC patients tissue samples demonstrated significant differences in cellular proximity neighbourhoods, cell type specific abundance and expression between the early and late recurrence samples. We discover that macrophages show spatial association with the blood vessels in early recurrence samples. Moreover, we observed conglomeration of B cells and macrophages with Tregulatory, Thelper and Tcytotoxic cells in association with early recurrences. We showed that stromal abundance of Tregulatory, Thelper, Tcytotoxic cells and monocytes are significantly in late, and no recurrence samples compared to early recurrence samples. The most differential expression profile that differentiates late and no recurrence samples from the early recurrence samples is related to the stem cell population. Particularly, we found overexpression of GLUT1, FLIP and downregulation of BAX, BAK, MLKL and CDX2 proteins in the cancer stem cell of early recurrence samples. We built a neural network based on the cancer stem cell protein signature (BAX, MLKL, FLIP, GLUT1 and CDX2 proteins) that delivers a high-performance prognostic classifier. How this study might affect research, practice or policy: Our results propose a clinically promising prognostic tool based on a five-protein stem cell signature that outperforms existing clinical and proposed transcriptomic based signatures for separation between risk groups. Moreover, our five-protein signature markers not only predict stem cell chemotherapy resistance and therefore tumour recurrence but also suggest potential therapeutic strategies. For instance, this approach could guide combinatorial treatments at high risk of chemoresistance, such as incorporating small molecule inhibitors targeting FLIP (currently in discovery phase) and GLUT1 (already under preclinical trial evaluation).

18 July 2025 in bioRxiv
Verified
Preprint
Open access
EBEmir Bozkurt
Emir Bozkurt
BKBatuhan Kisakol
Batuhan Kisakol
HDHeiko Dussmann
Heiko Dussmann
FLFederico Lucantoni
Federico Lucantoni
ASAnna Sturrock
Anna Sturrock
Jochen PrehnJochen Prehn
Jochen Prehn
Cell competition is an emerging mechanism in which mammalian tissues maintain homeostasis by eliminating less fit (loser) cells through direct interactions with fitter (winner) neighbouring cells. In cancer, these competitive interactions may drive tumour evolution; however, spatial organisation and clinical relevance of these events remain poorly understood. One mechanism by which winner cells eliminate loser cells is engulfment, resulting in cell-in-cell (CIC) formation. Although CICs have been observed in many tumour types for over a century, their cellular composition, spatial context, interactions with the tumour microenvironment, and biological significance in human cancers remain unclear. Here, we systematically characterised the cellular identity and functional states of CICs in situ , examined their spatial interactions within the tumour microenvironment, and assessed their clinical relevance using spatially resolved single-cell data from a large cohort of colorectal cancer patients. We demonstrate that CICs occur predominantly between cancer cells but also involve cancer stem cell (CSC)-like populations and cytotoxic T cells. Engulfed (inner) cancer and CSC-like cells display molecular features consistent with a loser-cell phenotype, including increased apoptosis and reduced proliferation, whereas outer cancer cells exhibit winner-cell features such as upregulated glycolysis. Live-cell time-lapse experiments demonstrate that glucose accumulates in inner cells during lysosomal degradation following cell engulfment. Spatial analysis further revealed distinct CIC neighbourhoods, which we defined based on proximity to engulfment events. Cells within these regions, particularly CSC-like cells and cytotoxic T cells, exhibit increased metabolic stress, suggesting local competition for nutrients. Importantly, the presence of cytotoxic T cells within CIC neighbourhoods and spatial co-occurrence patterns between cancer cells and CSC-like populations are associated with improved patient outcomes. Together, our findings demonstrate that cell engulfment defines spatially organised competitive niches and may reflect cell competition within complex tumour microenvironments.